2019
Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer
Tan W, Krimphove M, Cole A, Marchese M, Berg S, Lipsitz S, Löppenberg B, Nabi J, Abdollah F, Choueiri T, Kibel A, Sooriakumaran P, Trinh Q. Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clinical Genitourinary Cancer 2019, 17: e1060-e1068. PMID: 31303561, DOI: 10.1016/j.clgc.2019.06.008.Peer-Reviewed Original ResearchConceptsPositive surgical marginsFactors associated with positive surgical marginsPositive surgical margin statusPT2 prostate cancerRadical prostatectomyProstate cancerCancer-specific factorsSurgical approachMargin statusHigher hospital surgical volumeSurgical margin statusNational Cancer DatabaseHospital surgical volumeCancer-specific featuresPSM rateSurgical marginsCancer DatabaseImprove patient outcomesEvaluating patientsContribution of patientLogistic regression modelsSurgical volumeProstatectomyPatientsPatient-specific
2017
Abstract 5702: A targeted re-sequencing assay for molecular profiling of somatic mutations from plasma cell-free dna (cfdna) for bladder cancers
Dong L, Khetrapal P, Rodney S, Tan W, Rezaee S, Winter P, Kelly J, Feber A. Abstract 5702: A targeted re-sequencing assay for molecular profiling of somatic mutations from plasma cell-free dna (cfdna) for bladder cancers. Cancer Research 2017, 77: 5702-5702. DOI: 10.1158/1538-7445.am2017-5702.Peer-Reviewed Original ResearchPlasma cell-free DNAProfiles of somatic mutationsCell-free DNAMetastatic BCBladder cancerNext generation sequencingSomatic mutationsAmerican Association for Cancer Research annual meetingsCfDNA samplesMolecular profilingStratify patient managementResponse to chemotherapyMonitoring treatment responseAbstract Bladder cancerDetect somatic mutationsTechnical duplicatesAllele frequenciesIllumina MiSeq sequencing platformNext generation sequencing workflowMutational burdenTumor DNAImprove patient outcomesMiSeq sequencing platformTreatment responseTumor heterogeneity